Zacks Research Forecasts Stronger Earnings for AngioDynamics

AngioDynamics, Inc. (NASDAQ:ANGO) – Stock analysts at Zacks Research raised their Q2 2026 earnings per share estimates for shares of AngioDynamics in a research note issued to investors on Thursday, March 6th. Zacks Research analyst D. Dey now forecasts that the medical instruments supplier will post earnings of ($0.10) per share for the quarter, up from their prior forecast of ($0.11). The consensus estimate for AngioDynamics’ current full-year earnings is ($0.37) per share. Zacks Research also issued estimates for AngioDynamics’ Q3 2026 earnings at ($0.04) EPS, Q4 2026 earnings at $0.01 EPS, FY2026 earnings at ($0.27) EPS and FY2027 earnings at ($0.17) EPS.

Separately, HC Wainwright lifted their target price on shares of AngioDynamics from $14.00 to $15.00 and gave the company a “buy” rating in a research note on Friday, January 10th.

AngioDynamics Stock Up 9.0 %

NASDAQ:ANGO opened at $9.12 on Monday. The firm’s fifty day simple moving average is $10.82 and its 200 day simple moving average is $8.60. The stock has a market cap of $369.05 million, a P/E ratio of -1.62 and a beta of 0.57. AngioDynamics has a twelve month low of $5.26 and a twelve month high of $13.50.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings data on Wednesday, January 8th. The medical instruments supplier reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.07. The firm had revenue of $72.90 million for the quarter, compared to analyst estimates of $70.93 million. AngioDynamics had a negative return on equity of 7.26% and a negative net margin of 79.38%. The business’s quarterly revenue was down .1% compared to the same quarter last year. During the same period last year, the company earned ($0.05) EPS.

Institutional Investors Weigh In On AngioDynamics

Several hedge funds have recently bought and sold shares of the business. Segall Bryant & Hamill LLC increased its stake in shares of AngioDynamics by 142.7% during the third quarter. Segall Bryant & Hamill LLC now owns 911,443 shares of the medical instruments supplier’s stock valued at $7,091,000 after purchasing an additional 535,958 shares in the last quarter. Divisadero Street Capital Management LP bought a new position in AngioDynamics during the 4th quarter valued at approximately $4,714,000. Marshall Wace LLP increased its position in AngioDynamics by 1,335.1% during the 4th quarter. Marshall Wace LLP now owns 476,824 shares of the medical instruments supplier’s stock valued at $4,368,000 after buying an additional 443,598 shares in the last quarter. Paradigm Capital Management Inc. NY purchased a new position in AngioDynamics during the fourth quarter valued at $3,701,000. Finally, Nuveen Asset Management LLC boosted its holdings in AngioDynamics by 37.4% in the fourth quarter. Nuveen Asset Management LLC now owns 1,296,366 shares of the medical instruments supplier’s stock worth $11,875,000 after acquiring an additional 353,070 shares in the last quarter. Institutional investors own 89.43% of the company’s stock.

Insider Activity

In other news, SVP Warren Nighan, Jr. sold 4,060 shares of the company’s stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $12.31, for a total value of $49,978.60. Following the sale, the senior vice president now directly owns 41,817 shares of the company’s stock, valued at $514,767.27. This represents a 8.85 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 5.40% of the stock is currently owned by company insiders.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.